Abstract
BACKGROUND: Patients with cystic fibrosis have received more intravenous antibiotic courses as median survival has steadily increased. A number of centres have adopted a policy of regular (three monthly) rather than on demand intravenous antipseudomonal antibiotics. More widespread bacterial antibiotic resistance has resulted from this increased antibiotic use. Most Pseudomonas aeruginosa strains remain fully sensitive to colistin but its use has been resisted owing to concerns about neurotoxicity and nephrotoxicity. A study was carried out to assess the safety and efficacy of intravenous colistin in the treatment of acute respiratory exacerbations in adult patients with cystic fibrosis. METHODS: Patients with chronic Pseudomonas aeruginosa colonisation who presented with protocol defined respiratory tract exacerbations were randomised to receive treatment for 12 days with either colistin (2 MU tds intravenously) alone or with a second anti- pseudomonal antibiotic. Comparisons of the absolute values of respiratory function tests on days 1, 5, and 12 and of overnight oxygen saturation on days 1 and 12 were the primary outcome measures. Patient's weight, clinical and chest radiographic scores, and peripheral blood markers of inflammation were also documented. The effect of each treatment regimen individually was assessed by the change in clinical measurements from baseline values. Adverse renal effects were monitored by measurement of serum levels of urea and electrolytes, creatinine clearance, and ward urine testing. Neurotoxicity was monitored by direct questioning for symptoms. RESULTS: Fifty three patients, 18 of whom entered the study twice, were enrolled. The mean forced expiratory volume in one second (FEV1) increased significantly in both groups, mean forced vital capacity (FVC) only with dual therapy. Both groups showed a non-significant increase in overnight oxygen saturation. All patients showed clinical improvement. Thirty seven adverse neurological events (two severe) were reported in 33 patients in the monotherapy group and 37 (none severe) in 36 patients in the dual therapy group. One patient withdrew because of severe weakness and dizziness. All other adverse neurological events were well tolerated and resolved during or shortly after treatment. Significant changes were seen in mean serum urea levels in both groups, but in only four patients to a level above the normal range, and in creatinine clearance in the dual therapy group. At 24 month follow up no long term adverse consequences from intravenous colistin were found in patients who completed the study. CONCLUSIONS: Intravenous colistin is an effective treatment for Pseudomonas aeruginosa associated pulmonary exacerbations in patients with cystic fibrosis. Assessment of the individual effect of each treatment regimen suggests a greater efficacy when colistin is combined with a second antibiotic to which the pseudomonas shows in vitro sensitivity. Changes in renal function should be monitored.
Full Text
The Full Text of this article is available as a PDF (140.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bosso J. A., Liptak C. A., Seilheimer D. K., Harrison G. M. Toxicity of colistin in cystic fibrosis patients. DICP. 1991 Nov;25(11):1168–1170. doi: 10.1177/106002809102501101. [DOI] [PubMed] [Google Scholar]
- Chrispin A. R., Norman A. P. The systematic evaluation of the chest radiograph in cystic fibrosis. Pediatr Radiol. 1974;2(2):101–105. doi: 10.1007/BF01314939. [DOI] [PubMed] [Google Scholar]
- Conway S. P., Pond M. N., Bowler I., Smith D. L., Simmonds E. J., Joanes D. N., Hambleton G., Hiller E. J., Stableforth D. E., Weller P. The chest radiograph in cystic fibrosis: a new scoring system compared with the Chrispin-Norman and Brasfield scores. Thorax. 1994 Sep;49(9):860–862. doi: 10.1136/thx.49.9.860. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cox C. E., Harrison L. H. Intravenous sodium colistimethate therapy of urinary-tract infections: pharmacological and bacteriological studies. Antimicrob Agents Chemother (Bethesda) 1970;10:296–302. [PubMed] [Google Scholar]
- Dodge J. A., Morison S., Lewis P. A., Colest E. C., Geddes D., Russell G., Jackson A. D., Bentley B. Cystic fibrosis in the United Kingdom, 1968-1988: incidence, population and survival. Paediatr Perinat Epidemiol. 1993 Apr;7(2):157–166. doi: 10.1111/j.1365-3016.1993.tb00390.x. [DOI] [PubMed] [Google Scholar]
- Elborn J. S., Shale D. J., Britton J. R. Cystic fibrosis: current survival and population estimates to the year 2000. Thorax. 1991 Dec;46(12):881–885. doi: 10.1136/thx.46.12.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Froman J., Gross L., Curatola S. Serum and urine levels following parenteral administration of sodium colistimethate to normal individuals. J Urol. 1970 Feb;103(2):210–214. doi: 10.1016/s0022-5347(17)61924-4. [DOI] [PubMed] [Google Scholar]
- Gold G. N., Richardson A. P., Jr An unusual case of neuromuscular blockade seen with therapeutic blood levels of colistin methanesulfonate (Coly-Mycin). Am J Med. 1966 Aug;41(2):316–321. doi: 10.1016/0002-9343(66)90026-x. [DOI] [PubMed] [Google Scholar]
- Kearns G. L., Hilman B. C., Wilson J. T. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr. 1982 Feb;100(2):312–318. doi: 10.1016/s0022-3476(82)80663-x. [DOI] [PubMed] [Google Scholar]
- Koch-Weser J., Sidel V. W., Federman E. B., Kanarek P., Finer D. C., Eaton A. E. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970 Jun;72(6):857–868. doi: 10.7326/0003-4819-72-6-857. [DOI] [PubMed] [Google Scholar]
- Lindsay C. A., Bosso J. A. Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations. Clin Pharmacokinet. 1993 Jun;24(6):496–506. doi: 10.2165/00003088-199324060-00005. [DOI] [PubMed] [Google Scholar]
- Mouton J. W., den Hollander J. G., Horrevorts A. M. Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother. 1993 Jun;31(6):919–926. doi: 10.1093/jac/31.6.919. [DOI] [PubMed] [Google Scholar]
- Olesen S., Madsen P. O. Intravenous administration of sodium colistimethate in urinary tract infections. Curr Ther Res Clin Exp. 1967 Jun;9(6):283–287. [PubMed] [Google Scholar]
- Parry M. F., Neu H. C., Merlino M., Gaerlan P. F., Ores C. N., Denning C. R. Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. J Pediatr. 1977 Jan;90(1):144–148. doi: 10.1016/s0022-3476(77)80790-7. [DOI] [PubMed] [Google Scholar]
- Pedersen S. S., Koch C., Høiby N., Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother. 1986 Apr;17(4):505–516. doi: 10.1093/jac/17.4.505. [DOI] [PubMed] [Google Scholar]
- Pines A., Raafat H., Plucinski K. Gentamicin and colistin in chronic purulent bronchial infections. Br Med J. 1967 May 27;2(5551):543–545. doi: 10.1136/bmj.2.5551.543. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Prandota J. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs. 1988 May;35(5):542–578. doi: 10.2165/00003495-198835050-00004. [DOI] [PubMed] [Google Scholar]
- Price D. J., Graham D. I. Effects of large doses of colistin sulphomethate sodium on renal function. Br Med J. 1970 Nov 28;4(5734):525–527. doi: 10.1136/bmj.4.5734.525. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Regelmann W. E., Elliott G. R., Warwick W. J., Clawson C. C. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis. 1990 Apr;141(4 Pt 1):914–921. doi: 10.1164/ajrccm/141.4_Pt_1.914. [DOI] [PubMed] [Google Scholar]
- SHWACHMAN H., KULCZYCKI L. L. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. AMA J Dis Child. 1958 Jul;96(1):6–15. doi: 10.1001/archpedi.1958.02060060008002. [DOI] [PubMed] [Google Scholar]
- Smith A. L., Redding G., Doershuk C., Goldmann D., Gore E., Hilman B., Marks M., Moss R., Ramsey B., Rubio T. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr. 1988 Apr;112(4):547–554. doi: 10.1016/s0022-3476(88)80165-3. [DOI] [PubMed] [Google Scholar]
- Szaff M., Høiby N., Flensborg E. W. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand. 1983 Sep;72(5):651–657. doi: 10.1111/j.1651-2227.1983.tb09789.x. [DOI] [PubMed] [Google Scholar]
- WOLINSKY E., HINES J. D. Neurotoxic and nephrotoxic effects of colistin patients with renal disease. N Engl J Med. 1962 Apr 12;266:759–762. doi: 10.1056/NEJM196204122661505. [DOI] [PubMed] [Google Scholar]